These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1368 related articles for article (PubMed ID: 25916341)

  • 21. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.
    Berkowitz EM; Moyle G; Stellbrink HJ; Schürmann D; Kegg S; Stoll M; El Idrissi M; Oostvogels L; Heineman TC;
    J Infect Dis; 2015 Apr; 211(8):1279-87. PubMed ID: 25371534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.
    Chlibek R; Bayas JM; Collins H; de la Pinta ML; Ledent E; Mols JF; Heineman TC
    J Infect Dis; 2013 Dec; 208(12):1953-61. PubMed ID: 23904292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Andriolo BN; Torloni MR; Soares BG
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD008858. PubMed ID: 26937872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly.
    Vink P; Shiramoto M; Ogawa M; Eda M; Douha M; Heineman T; Lal H
    Hum Vaccin Immunother; 2017 Mar; 13(3):574-578. PubMed ID: 27936344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
    Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
    Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
    López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
    Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.
    López-Fauqued M; Campora L; Delannois F; El Idrissi M; Oostvogels L; De Looze FJ; Diez-Domingo J; Heineman TC; Lal H; McElhaney JE; McNeil SA; Yeo W; Tavares-Da-Silva F;
    Vaccine; 2019 Apr; 37(18):2482-2493. PubMed ID: 30935742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study.
    Chlibek R; Smetana J; Pauksens K; Rombo L; Van den Hoek JA; Richardus JH; Plassmann G; Schwarz TF; Ledent E; Heineman TC
    Vaccine; 2014 Mar; 32(15):1745-53. PubMed ID: 24508036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination: a new option to reduce the burden of herpes zoster.
    Mick G
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.
    Dagnew AF; Rausch D; Hervé C; Zahaf T; Levin MJ; Schuind A;
    Rheumatology (Oxford); 2021 Mar; 60(3):1226-1233. PubMed ID: 32910152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Herpes zoster subunit vaccine for the prevention of herpes zoster.
    Symoniak MR; Farrokh P; Gandhi MA; Slish JC
    Am J Health Syst Pharm; 2018 Jun; 75(12):861-869. PubMed ID: 29880523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Gomes Silva BN; Torloni MR; Soares BG
    Cochrane Database Syst Rev; 2012 Oct; 10():CD008858. PubMed ID: 23076951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients.
    Ocran-Appiah J; Boutry C; Hervé C; Soni J; Schuind A;
    Vaccine; 2021 Jan; 39(1):6-10. PubMed ID: 33277059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults.
    Schwarz TF; Volpe S; Catteau G; Chlibek R; David MP; Richardus JH; Lal H; Oostvogels L; Pauksens K; Ravault S; Rombo L; Sonder G; Smetana J; Heineman T; Bastidas A
    Hum Vaccin Immunother; 2018 Jun; 14(6):1370-1377. PubMed ID: 29461919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine.
    James SF; Chahine EB; Sucher AJ; Hanna C
    Ann Pharmacother; 2018 Jul; 52(7):673-680. PubMed ID: 29457489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
    Russell AF; Parrino J; Fisher CL; Spieler W; Stek JE; Coll KE; Su SC; Xu J; Li X; Schlienger K; Silber JL
    Vaccine; 2015 Jun; 33(27):3129-34. PubMed ID: 25964168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial.
    Mullane KM; Morrison VA; Camacho LH; Arvin A; McNeil SA; Durrand J; Campbell B; Su SC; Chan ISF; Parrino J; Kaplan SS; Popmihajlov Z; Annunziato PW;
    Lancet Infect Dis; 2019 Sep; 19(9):1001-1012. PubMed ID: 31399378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Vaccines against varicella-zoster virus (VZV)].
    Salleras L; Salleras M; Soldevila N; Prat A; Garrido P; Domínguez Á
    Enferm Infecc Microbiol Clin; 2015; 33(6):411-23. PubMed ID: 26096575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.
    Oostvogels L; Heineman TC; Johnson RW; Levin MJ; McElhaney JE; Van den Steen P; Zahaf T; Dagnew AF; Chlibek R; Diez-Domingo J; Gorfinkel IS; Hervé C; Hwang SJ; Ikematsu H; Kalema G; Lal H; McNeil SA; Mrkvan T; Pauksens K; Smetana J; Watanabe D; Weckx LY; Cunningham AL
    Hum Vaccin Immunother; 2019; 15(12):2865-2872. PubMed ID: 31216205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.
    Tyring SK; Diaz-Mitoma F; Padget LG; Nunez M; Poland G; Cassidy WM; Bundick ND; Li J; Chan IS; Stek JE; Annunziato PW;
    Vaccine; 2007 Feb; 25(10):1877-83. PubMed ID: 17227688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 69.